What happened in this Health story?

The FDA released draft guidance to accelerate approval of individualized gene therapies, a move welcomed by rare disease advocates seeking faster access to personalized treatments.

What is a key fact in this story? (1)

**FDA** published draft guidance on Tuesday to streamline approvals for individualized gene therapies, aiming to reduce regulatory hurdles for personalized treatments.

What is a key fact in this story? (2)

**Paul Scribner** of the PKD Foundation said the guidance signals that the FDA recognizes the importance of advancing personalized therapies for rare diseases.

📎 SkimNews has covered FDA 86+ times · see the file →

FDA Proposes Faster Approval Path for Gene Therapies — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-10-27

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

FDA published draft guidance on Tuesday to streamline approvals for individualized gene therapies, aiming to reduce regulatory hurdles for personalized treatments.
Paul Scribner of the PKD Foundation said the guidance signals that the FDA recognizes the importance of advancing personalized therapies for rare diseases.
Gene therapy researchers and companies are energized by breakthroughs enabling treatments that correct faulty genes, with potential to help patients with rare genetic mutations.
Rare disease advocates have previously criticized the FDA’s regulatory approach as too slow for individualized gene therapies, making this guidance a significant shift.

Why it matters: Patients with ultra-rare mutations could gain faster access to life-altering therapies, as the FDA’s new pathway reduces development time and cost for sponsors targeting small populations—potentially accelerating the arrival of first-in-kind treatments to market.